Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction
Authors
Keywords
Cardiovascular outcome trials, Icosapent ethyl, Eicosapentaenoic acid, Docosahexaenoic acid, Triglycerides, REDUCE-IT, STRENGTH
Journal
METABOLISM-CLINICAL AND EXPERIMENTAL
Volume -, Issue -, Pages 155161
Publisher
Elsevier BV
Online
2022-02-10
DOI
10.1016/j.metabol.2022.155161
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects
- (2021) Anthony D. Pisaniello et al. ATHEROSCLEROSIS
- EPA and DHA differentially modulate membrane elasticity in the presence of cholesterol
- (2021) Miranda L. Jacobs et al. BIOPHYSICAL JOURNAL
- Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk
- (2021) Steven E. Nissen et al. JAMA Cardiology
- Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention
- (2021) Karan Kapoor et al. Journal of Clinical Lipidology
- Eicosapentaenoic acid membrane incorporation stimulates ABCA1-mediated cholesterol efflux from human THP-1 macrophages
- (2021) Hani Dakroub et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Effect of Omega-3 Fatty Acids on Coronary Plaque Morphology ― A Serial Computed Tomography Angiography Study ―
- (2021) Sadako Motoyama et al. CIRCULATION JOURNAL
- Changes in EPA and DHA during supplementation with omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial
- (2021) P Myhre et al. EUROPEAN HEART JOURNAL
- Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability
- (2021) Samuel C.R. Sherratt et al. PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
- Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro
- (2020) Samuel C.R. Sherratt et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
- (2020) R. Preston Mason et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
- (2020) Matthew J Budoff et al. EUROPEAN HEART JOURNAL
- Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
- (2020) Brian Olshansky et al. EUROPEAN HEART JOURNAL SUPPLEMENTS
- Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial
- (2020) Are Annesønn Kalstad et al. CIRCULATION
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
- (2020) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Preferential Incorporation of Administered Eicosapentaenoic Acid Into Thin-Cap Atherosclerotic Plaques
- (2019) Tomohito Sato et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin
- (2018) R. Preston Mason et al. BIOMEDICINE & PHARMACOTHERAPY
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins
- (2017) Tetsu Watanabe et al. Journal of Cardiology
- Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial
- (2017) Abdulhamied Alfaddagh et al. Journal of the American Heart Association
- Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes
- (2016) R. Preston Mason et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents
- (2016) R. Preston Mason et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma
- (2014) Ryo Nishio et al. ATHEROSCLEROSIS
- Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
- (2013) Harold E. Bays et al. American Journal of Cardiovascular Drugs
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now